Stoke Therapeutics (STOK) Free Cash Flow Growth (3y) (2021 - 2026)
Stoke Therapeutics (STOK) Free Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.89 Bn | 468.10 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 122.12 Bn | 114.87 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.72 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.47 Bn | 34.46 Bn | 959.66 Mn | 31.42% |
| 10 | Stoke Therapeutics | 1.87 Bn | 1.53 Bn | - | -41.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.47% |
| Dec 31, 2025 | -12.00% |
| Sep 30, 2025 | -11.89% |
| Jun 30, 2025 | -8.65% |
| Mar 31, 2025 | 60.88% |
| Dec 31, 2024 | -12.26% |
| Sep 30, 2024 | -12.98% |
| Jun 30, 2024 | -2.35% |
| Mar 31, 2024 | -6.50% |
| Dec 31, 2023 | -24.34% |
| Sep 30, 2023 | -17.38% |
| Jun 30, 2023 | -32.87% |
| Mar 31, 2023 | -25.82% |
| Dec 31, 2022 | -27.06% |
| Sep 30, 2022 | -35.99% |
| Jun 30, 2022 | -43.85% |
| Mar 31, 2022 | 89.25% |
| Dec 31, 2021 | -66.08% |
| Sep 30, 2021 | -61.40% |